This inventor holds 2 USPTO granted patents and 7 published patent applications and 3 EPO patents. Top assignee: Mission Therapeutics Limited. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Christopher Andrew Luckhurst: Innovator in Therapeutics
Introduction
Christopher Andrew Luckhurst is an inventor based in Cambridge, GB. He is currently associated with Mission Therapeutics Limited, where he contributes to the field of therapeutic innovations. Although he has not yet been granted any patents, his work is focused on developing novel compounds with significant potential in treating various medical conditions.
Latest Patent Applications
Christopher's latest patent applications include:
1. **Substituted N-Cyanopyrrolidines with Activity as USP30 Inhibitors** - This invention relates to a class of substituted N-cyanopyrrolidines that act as inhibitors of the deubiquitylating enzyme USP30. These compounds have utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer, and fibrosis.
2. **N-Cyanopyrrolidines with Activity as USP30 Inhibitors** - This application also pertains to a class of N-cyanopyrrolidines with activity as inhibitors of USP30, aimed at addressing similar therapeutic needs as mentioned above.
Conclusion
Christopher Andrew Luckhurst is making strides in the field of therapeutics through his innovative research and patent applications. His contributions may lead to significant advancements in treating complex medical conditions.